PBF-509 is a Small Molecule owned by Novartis, and is involved in 7 clinical trials, of which 3 were completed, and 4 are ongoing.
PBF-509 (NIR-178) works by inhibiting adenosine A2A receptor and programmed cell death protein 1 (PD-1). Adenosine A2A receptors are selectively expressed in the basal ganglia that also express dopamine D2 receptors. Blockade of the A2A receptor in striatopallidal neurons reduces postsynaptic effects of dopamine depletion and reduces the motor deficits of Parkinson's disease. The drug candidate also works by decreasing excessive accumulation of adenosine that mobilizes intracellular calcium ions. PD-1 is a cell surface receptor protein which interacts with programmed cell death ligand 1 (PD-L1) to inhibit T cell proliferation and cytokine production. Blocking of PD-1 by the drug prevents immunosuppression.The drug candidate by preventing the death of neurons in the brain and elicits therapeutic intervention.
The revenue for PBF-509 is expected to reach a total of $832m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the PBF-509 NPV Report.
PBF-509 (NIR-178) is under development for the treatment of solid tumors including non-small cell lung cancer, renal cell carcinoma, melanoma, pancreatic cancer, colon cancer, head and neck cancer, bladder cancer, triple-negative breast cancer, urothelial cancer, non-hodgkin lymphoma, metastatic hormone refractory prostate cancer and diffuse large B-cell lymphoma. It is administered orally and is a non-furan compound targeting adenosine A2A receptor. It was also under development for Parkinson's disease, attention deficit hyperactivity disorder (ADHD),and Type 2 diabetes.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.
Quick View – PBF-509
|Highest Development Stage|